AAAAAA

   
Results: 1-25 | 26-26
Results: 1-25/26
Randomized, placebo-controlled, double-blind trial with interferon-alpha with and without amantadine sulphate in primary interferon-alpha nonresponders with chronic hepatitis C
Authors: Teuber, G Berg, T Naumann, U Raedle, J Brinkmann, S Hopf, U Zeuzem, S
Citation: G. Teuber et al., Randomized, placebo-controlled, double-blind trial with interferon-alpha with and without amantadine sulphate in primary interferon-alpha nonresponders with chronic hepatitis C, J VIRAL HEP, 8(4), 2001, pp. 276-283
APRIL, a new member of the tumor necrosis factor family, modulates death ligand-induced apoptosis
Authors: Roth, W Wagenknecht, B Klumpp, A Naumann, U Hahne, M Tschopp, J Weller, M
Citation: W. Roth et al., APRIL, a new member of the tumor necrosis factor family, modulates death ligand-induced apoptosis, CELL DEAT D, 8(4), 2001, pp. 403-410
CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release
Authors: Rohn, TA Wagenknecht, B Roth, W Naumann, U Gulbins, E Krammer, PH Walczak, H Weller, M
Citation: Ta. Rohn et al., CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release, ONCOGENE, 20(31), 2001, pp. 4128-4137
Pilot study of interferon-alpha high-dose induction therapy in combinationwith ribavirin plus amantadine for nonresponder patients with chronic hepatitis C
Authors: Berg, T Naumann, U Wiedenmann, B Hopf, U
Citation: T. Berg et al., Pilot study of interferon-alpha high-dose induction therapy in combinationwith ribavirin plus amantadine for nonresponder patients with chronic hepatitis C, Z GASTROENT, 39(2), 2001, pp. 145
Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive patients undergoing liver transplantation
Authors: Seehofer, D Rayes, N Naumann, U Neuhaus, R Muller, AR Tullius, SG Berg, T Steinmuller, T Bechstein, WO Neuhaus, P
Citation: D. Seehofer et al., Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive patients undergoing liver transplantation, TRANSPLANT, 72(8), 2001, pp. 1381-1385
Comparison of famciclovir and lamivudine in the long-term treatment of hepatitis B infection after liver transplantation
Authors: Rayes, N Seehofer, D Hopf, U Neuhaus, R Naumann, U Bechstein, WO Neuhaus, P
Citation: N. Rayes et al., Comparison of famciclovir and lamivudine in the long-term treatment of hepatitis B infection after liver transplantation, TRANSPLANT, 71(1), 2001, pp. 96-101
Processing of immunosuppressive pro-TGF-beta 1,2 by human glioblastoma cells involves cytoplasmic and secreted furin-like proteases
Authors: Leitlein, J Aulwurm, S Waltereit, R Naumann, U Wagenknecht, B Garten, W Weller, M Platten, M
Citation: J. Leitlein et al., Processing of immunosuppressive pro-TGF-beta 1,2 by human glioblastoma cells involves cytoplasmic and secreted furin-like proteases, J IMMUNOL, 166(12), 2001, pp. 7238-7243
Chromosomal imbalances associated with response to chemotherapy and cytotoxic cytokines in human malignant glioma eel lines
Authors: Weber, RG Rieger, J Naumann, U Lichter, P Weller, M
Citation: Rg. Weber et al., Chromosomal imbalances associated with response to chemotherapy and cytotoxic cytokines in human malignant glioma eel lines, INT J CANC, 91(2), 2001, pp. 213-218
Diva/Boo is a negative regulator of cell death in human glioma cells
Authors: Naumann, U Weit, S Wischhusen, J Weller, M
Citation: U. Naumann et al., Diva/Boo is a negative regulator of cell death in human glioma cells, FEBS LETTER, 505(1), 2001, pp. 23-26
Glioma cell sensitivity to topotecan: the role of p53 and topotecan-induced DNA damage
Authors: Schmidt, F Rieger, J Wischhusen, J Naumann, U Weller, M
Citation: F. Schmidt et al., Glioma cell sensitivity to topotecan: the role of p53 and topotecan-induced DNA damage, EUR J PHARM, 412(1), 2001, pp. 21-25
Chimeric tumor suppressor 1, a p53-derived chimeric tumor suppressor gene,kills p53 mutant and p53 wild-type glioma cells in synergy with irradiation and CD95 ligand
Authors: Naumann, U Kugler, S Wolburg, H Wick, W Rascher, G Schulz, JB Conseiller, E Bahr, M Weller, M
Citation: U. Naumann et al., Chimeric tumor suppressor 1, a p53-derived chimeric tumor suppressor gene,kills p53 mutant and p53 wild-type glioma cells in synergy with irradiation and CD95 ligand, CANCER RES, 61(15), 2001, pp. 5833-5842
Randomized, double-blind, placebo-controlled trial of interferon Alfa2a with and without amantadine as initial treatment for chronic hepatitis C
Authors: Zeuzem, S Teuber, G Naumann, U Berg, T Raedle, J Hartmann, S Hopf, U
Citation: S. Zeuzem et al., Randomized, double-blind, placebo-controlled trial of interferon Alfa2a with and without amantadine as initial treatment for chronic hepatitis C, HEPATOLOGY, 32(4), 2000, pp. 835-841
Antiviral therapy of recurrent hepatitis B infection after liver transplantation: A retrospective analysis of 200 liver transplants for hepatitis B related fiver diseases
Authors: Seehofer, D Rayes, N Bechstein, WO Naumann, U Neuhaus, R Berg, T Hopf, U Langrehr, JM Steinmuller, T Platz, KP Muller, AR Neuhaus, P
Citation: D. Seehofer et al., Antiviral therapy of recurrent hepatitis B infection after liver transplantation: A retrospective analysis of 200 liver transplants for hepatitis B related fiver diseases, Z GASTROENT, 38(9), 2000, pp. 773
Influence of ribavirin on the dynamics of hepatitis C viremia in interferon-alpha-treated patients with response or nonresponse
Authors: Berg, T Kaul, T Naumann, U Wiedenmann, B Hopf, U
Citation: T. Berg et al., Influence of ribavirin on the dynamics of hepatitis C viremia in interferon-alpha-treated patients with response or nonresponse, Z GASTROENT, 38(11), 2000, pp. 881-886
On the significance of telomerase activity in human malignant glioma cells
Authors: Vietor, M Winter, S Groscurth, P Naumann, U Weller, M
Citation: M. Vietor et al., On the significance of telomerase activity in human malignant glioma cells, EUR J PHARM, 407(1-2), 2000, pp. 27-37
Expression and biological activity of X-linked inhibitor of apoptosis (XIAP) in human malignant glioma
Authors: Wagenknecht, B Glaser, T Naumann, U Kugler, S Isenmann, S Bahr, M Korneluk, R Liston, P Weller, M
Citation: B. Wagenknecht et al., Expression and biological activity of X-linked inhibitor of apoptosis (XIAP) in human malignant glioma, CELL DEAT D, 6(4), 1999, pp. 370-376
p53 enhances BAK and CD95 expression in human malignant glioma cells but does not enhance CD95L-induced apoptosis
Authors: Pohl, U Wagenknecht, B Naumann, U Weller, M
Citation: U. Pohl et al., p53 enhances BAK and CD95 expression in human malignant glioma cells but does not enhance CD95L-induced apoptosis, CELL PHYS B, 9(1), 1999, pp. 29-37
PTEN gene transfer in human malignant glioma: sensitization to irradiationand CD95L-induced apoptosis
Authors: Wick, W Furnari, FB Naumann, U Cavenee, WK Weller, M
Citation: W. Wick et al., PTEN gene transfer in human malignant glioma: sensitization to irradiationand CD95L-induced apoptosis, ONCOGENE, 18(27), 1999, pp. 3936-3943
Transforming growth factor-beta and p-21: multiple molecular targets of decorin-mediated suppression of neoplastic growth
Authors: Stander, M Naumann, U Wick, W Weller, M
Citation: M. Stander et al., Transforming growth factor-beta and p-21: multiple molecular targets of decorin-mediated suppression of neoplastic growth, CELL TIS RE, 296(2), 1999, pp. 221-227
Low-frequency repetitive transcranial magnetic stimulation improves intractable epilepsy
Authors: Tergau, F Naumann, U Paulus, W Steinhoff, BJ
Citation: F. Tergau et al., Low-frequency repetitive transcranial magnetic stimulation improves intractable epilepsy, LANCET, 353(9171), 1999, pp. 2209-2209
Treatment of hepatitis B-reinfection or de novo-infection after liver transplantation with famciclovir - How effective is it?
Authors: Rayes, N Neuhaus, R Naumann, U Hopf, U Haller, GW Bechstein, WO Neuhaus, P
Citation: N. Rayes et al., Treatment of hepatitis B-reinfection or de novo-infection after liver transplantation with famciclovir - How effective is it?, TRANSPLAN P, 31(1-2), 1999, pp. 481-482
Accumulation of mutant p53(V143A) modulates the growth, clonogenicity, andradiochemosensitivity of malignant glioma cells independent of endogenous p53 status
Authors: Bartussek, C Naumann, U Weller, M
Citation: C. Bartussek et al., Accumulation of mutant p53(V143A) modulates the growth, clonogenicity, andradiochemosensitivity of malignant glioma cells independent of endogenous p53 status, EXP CELL RE, 253(2), 1999, pp. 432-439
TGF-beta-independent induction of immunogenicity by decorin gene transfer in human malignant glioma cells
Authors: Munz, C Naumann, U Grimmel, C Rammensee, HG Weller, M
Citation: C. Munz et al., TGF-beta-independent induction of immunogenicity by decorin gene transfer in human malignant glioma cells, EUR J IMMUN, 29(3), 1999, pp. 1032-1040
Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity
Authors: Roth, W Isenmann, S Naumann, U Kugler, S Bahr, M Dichgans, J Ashkenazi, A Weller, M
Citation: W. Roth et al., Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity, BIOC BIOP R, 265(2), 1999, pp. 479-483
p27 modulates cell cycle progression and chemosensitivity in human malignant glioma
Authors: Naumann, U Weit, S Rieger, L Meyermann, R Weller, M
Citation: U. Naumann et al., p27 modulates cell cycle progression and chemosensitivity in human malignant glioma, BIOC BIOP R, 261(3), 1999, pp. 890-896
Risultati: 1-25 | 26-26